The artificial intelligence and machine learning in lung cancer immunotherapy
Open accessThe DOI matches its Crossref record; 81 of the 82 references it cites were found in a registry or an index.
Abstract
Since the past decades, more lung cancer patients have been experiencing lasting benefits from immunotherapy. It is imperative to accurately and intelligently select appropriate patients for immunotherapy or predict the immunotherapy efficacy. In recent years, machine learning (ML)-based artificial intelligence (AI) was developed in the area of medical-industrial convergence. AI can help model and predict medical information. A growing number of studies have combined radiology, pathology, genomics, proteomics data in order to predict the expression levels of programmed death-ligand 1 (PD-L1), tumor mutation burden (TMB) and tumor microenvironment (TME) in cancer patients or predict the likelihood of immunotherapy benefits and side effects. Finally, with the advancement of AI and ML, it is believed that "digital biopsy" can replace the traditional single assessment method to benefit more cancer patients and help clinical decision-making in the future. In this review, the applications of AI in PD-L1/TMB prediction, TME prediction and lung cancer immunotherapy are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 General process for AI-based PD-1/PD-L1 and TMB prediction. In the modeling process of machine learning, it generally goes through the process of feature collection, data preprocess, feature extraction, model establishment, performance evaluation, etc., and finally, obtains a prediction model. Abbreviation: WSI: Whole slide image. Created with BioRender.com. The heatmap was reprinted from Mol Cancer, Jin R, Liu B, Yu M, Song L, Gu M, Wang Z, et al. Profiling of DNA damage and repair pathways in small cell lung cancer reveals a suppressive role in the immune landscape. 2021;20(1):130, Copyright (2021) [80], licensed under CC BY 4.0 from Springer Nature](https://figures.cochat.ai/paper-figures/6a2eb42372db40c99a690b8ccb228453/the-artificial-intelligence-and-machine-learning-in-lung-cancer-immunotherapy-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“AI agents show significant potential in the realm of personalized treatment by leveraging a variety of patient-specific data, including genetic information, medical history, lifestyle factors, and treatment responses.77,88,89,90,91,92”
From A foundational architecture for AI agents in healthcare (2025) · cites this paper as [88]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“Moreover, there is compelling evidence to suggest that the spatial distribution of lymphocytes in TME (central versus infiltrating margins) is a highly predictive factor of cancer prognosis [36].”
BackgroundAccessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment
Hanahan, D., & Coussens, L. M. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.022 · Cited by 4,632 · cited 1×
“The immunosuppressive TME in lung cancer has been shown to promote tumorigenesis [34, 35].”
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446
Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T., & Nijman, H. W. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.189 · Cited by 1,277
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00174 · Cited by 1,159
Saltz, J., Gupta, R., Hou, L., Kurc, T., Singh, P., Nguyen, V., Samaras, D., Shroyer, K. R., Zhao, T., Batiste, R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.086 · Cited by 1,027
Self-citationHistory of artificial intelligence in medicine
Kaul, V., Enslin, S., & Gross, S. A. (2020) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2020.06.040 · Cited by 1,011
Dermatologic Reactions to Immune Checkpoint Inhibitors: Skin Toxicities and Immunotherapy
Sibaud, V. (2018) · American Journal of Clinical Dermatology · doi:10.1007/s40257-017-0336-3 · Cited by 626
Cited by
Fahim, Y. A., Hasani, I. W., Kabba, S., & Ragab, W. M. (2025) · European Journal of Medical Research · doi:10.1186/s40001-025-03196-w · Cited by 329
“6 [112].”
Dixon, D., Sattar, H., Moros, N., Kesireddy, S. R., Ahsan, H., Lakkimsetti, M., Fatima, M., Doshi, D., Sadhu, K., & Junaid Hassan, M. (2024) · Cureus · doi:10.7759/cureus.59954 · Cited by 203
Artificial Intelligence and Lung Cancer: Impact on Improving Patient Outcomes
Gandhi, Z., Gurram, P., Amgai, B., Lekkala, S. P., Lokhandwala, A., Manne, S., Mohammed, A. S., Koshiya, H., Dewaswala, N., Desai, R., et al. (2023) · Cancers · doi:10.3390/cancers15215236 · Cited by 163
Parvin, N., Joo, S., Jung, J. H., & Mandal, T. K. (2025) · Nanomaterials · doi:10.3390/nano15120895 · Cited by 151
“…cancer therapeutics, these systems demonstrate a similar value by correlating tumor genomic landscapes with drug sensitivity patterns—as evidenced by recent non-small cell lung cancer research where an AI-guided therapy selection improved outcomes through mutation-specific treatment matching [92].”
Yogesh Kumaran, S., Jeya, J. J., Mahesh, T. R., Bhatia, S., Alzahrani, S., & Alojail, M. (2024) · BMC Medical Imaging · doi:10.1186/s12880-024-01345-x · Cited by 115
“The early detection and accurate classification of these manifestations into benign (non-cancerous) or malignant (cancerous) categories are crucial for effective treatment planning and improved patient outcomes [1, 2].”
Background
Metadata
- Authors
- Gao, Q., Yang, L., Lu, M., Jin, R., Ye, H., & Ma, T.
- Affiliations
- Capital Medical University (CN)
- Corresponding author
- Ma, Teng
- Venue
- Journal of Hematology & Oncology
- Published
- 2023-05-24
- Volume
- 16
- Issue
- 1
- Pages
- 55-55
- ISSN
- 1756-8722 (ISSN-L)
- PMC
- PMC10207827
- OpenAlex
- W4378172829
- Cited by
- 148
- References
- 82
- Citations by year
- 2026: 37 · 2025: 58 · 2024: 45 · 2023: 8
- FWCI
- 4.79
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Hematology & Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Beijing Xisike Clinical Oncology Research Foundation
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Radiomics and Machine Learning in Medical Imaging
- Physical Sciences › Computer Science › Artificial Intelligence › AI in cancer detection
- Keywords
- lung cancer, cancer immunotherapy, artificial intelligence, machine learning, tumor mutational burden, tumor microenvironment, immunotherapy response prediction, immunotherapy side effects, multi-omics integration
- MeSH terms
- Machine Learning, Artificial Intelligence, Humans, Immunotherapy, Lung Neoplasms, Tumor Microenvironment, B7-H1 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The artificial intelligence and machine learning in lung cancer immunotherapy. https://app.cochat.ai/papers/10.1186/s13045-023-01456-y
- The paper
- Gao, Q., Yang, L., Lu, M., Jin, R., Ye, H., & Ma, T. (2023). The artificial intelligence and machine learning in lung cancer immunotherapy. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-023-01456-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.